8-K: Replimune Group Appoints Michael Goller to Board, Enters Registration Rights Agreement with BBA Funds

Replimune Group, Inc. expands its Board of Directors with the appointment of Michael Goller and enters into an agreement granting Baker Brothers Life Sciences resale registration rights for their shares.

Summary

• Replimune Group, Inc. announced the appointment of Michael Goller to its Board of Directors, increasing the board size from nine to ten members.
• Mr. Goller will serve as a Class I director until the 2025 annual general meeting.
• The company entered into a registration rights agreement with 667, L.P. and Baker Brothers Life Sciences, L.P. (BBA Funds), granting them certain resale registration rights for their shares of common stock.
• Mr. Goller will receive an annual cash retainer of $45,000 for his board service and $5,000 for serving on the Nominating and Corporate Governance Committee.
• He also received a nonqualified stock option to acquire 64,000 shares of common stock at an exercise price of $12.29, vesting over three years.
• The BBA Funds have the right to one underwritten offering per calendar year, but no more than three in total, and no more than two underwritten offerings or block trades in any calendar year.
• The company is obligated to file a resale registration statement within 60 days of a request from the BBA Funds, subject to certain exceptions.

Sentiment

Score: 6

Explanation: The announcement is fairly neutral. The board appointment is generally positive, but the registration rights agreement introduces a potential risk of stock dilution. The sentiment is therefore moderately positive.

Positives

• The addition of Michael Goller to the Board of Directors could bring valuable expertise and insights.
• The Affiliate Registration Rights Agreement provides liquidity options for the BBA Funds, which could be seen as a positive sign of their continued investment in the company.
• Goller's compensation includes stock options, aligning his interests with those of shareholders.

Negatives

• The Affiliate Registration Rights Agreement could lead to increased selling pressure on the company's stock if the BBA Funds choose to exercise their registration rights.
• The company is obligated to pay certain expenses related to the registrations, which could impact its financial resources.

Risks

• The BBA Funds could request an underwritten offering, potentially diluting existing shareholders' equity.
• The company's obligation to file a resale registration statement could be burdensome and costly.
• The company may defer the filing of or suspend the use of any such Resale Registration Shelf or Prospectus, upon giving written notice of such action to the Investors with a certificate signed by the Chief Executive Officer of the Company stating that in the good faith judgment of the Board, the filing or use of any such Resale Registration Shelf or Prospectus covering the Registrable Securities would be seriously detrimental to the Company or its stockholders at such time and that the Board concludes, as a result, that it is in the best interests of the Company and its stockholders to defer the filing or suspend the use of such Resale Registration Shelf or Prospectus at such time.

Future Outlook

The company will file a resale registration statement on Form S-3, or other appropriate form, covering the Baker Registrable Securities following a request by the BBA Funds.

Industry Context

Registration rights agreements are common in the biotech industry, allowing significant investors to liquidate their holdings more easily. The appointment of a representative from a major investment firm to the board is also a typical move to align company strategy with investor interests.

Comparison to Industry Standards

• Similar biotech companies, such as BioNTech and Moderna, have registration rights agreements with their major shareholders.
• The terms of this agreement, including the number of underwritten offerings allowed per year, are within the typical range for such agreements in the biotech sector.
• The compensation structure for board members is also comparable to industry standards for companies of Replimune's size and stage.

Management Changes

Related Party Transactions

• The BBA Funds participated in the Company's private placement transaction in June 2024, purchasing shares and pre-funded warrants.
• The BBA Funds participated in the Company's underwritten public offering in November 2024, purchasing shares and pre-funded warrants.

Stakeholder Impact

• Shareholders may experience dilution if the BBA Funds exercise their registration rights and sell a significant number of shares.
• The appointment of Michael Goller to the board could influence the company's strategic direction.
• Employees may be affected by any changes in company strategy or financial performance resulting from these events.

Next Steps

• The company will file a resale registration statement on Form S-3, or other appropriate form, covering the Baker Registrable Securities following a request by the BBA Funds.
• Mr. Goller will serve as a Class I director until the Company's 2025 annual general meeting of shareholders.

Key Dates